5/5/2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

4/25/2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment

Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders

Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation

4/12/2022

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

3/23/2022

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

2/16/2022

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

2/1/2022

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

1/12/2022

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

1/4/2022

PharmaTher Announces Publication of Research Data for KETABET™

12/21/2021

PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

12/20/2021

PHARMATHER ENTERS INTO PROCESS DEVELOPMENT AGREEMENT WITH LTS LOHMANN FOR KETAMINE MICRONEEDLE PATCH

12/14/2021

PharmaTher Announces Positive Research Results for LSD Microneedle Patch

11/30/2021

PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

11/24/2021

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

11/11/2021

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

11/3/2021

News